Document Classification

Section Type: RESULTS

Text: At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0. 2 (P = 0. 80) and -1. 2 (P = 0. 34), respectively, in the carrier study ; the corresponding differences in the noncarrier study were -0. 3 (P = 0. 64) and 2. 8 (P = 0. 07) with the 0. 5-mg-per-kilogram dose of bapineuzumab and 0. 4 (P = 0. 62) and 0. 9 (P = 0. 55) with the 1. 0-mg-per-kilogram dose.